GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

GLP-1s linked to nutritional deficiencies in children

Children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes are at risk for nutritional deficiencies – diagnosed in nearly one in six patients (16.8%) within the first year – according to a new study published in the journal Childhood Obesity.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Experimental RNA therapy enhances weight loss while preserving lean muscle

GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight - primarily as fat.

21 Sep 2026

GLP-1 medications place children at risk for nutritional deficiencies

21 Sep 2026

New discovery overturns a prevailing model of brain development

For centuries, scientists have thought of the brain as a single, unified organ. But new research led by Stanford Medicine reveals that what we call the brain is two distinct organs that evolved independently over hundreds of millions of years.

18 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

14 Sep 2026

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.

10 Sep 2026

Symptomless liver condition linked to heart and kidney disease

A common liver condition thought to be harmless could be dramatically increasing the risk of heart disease, kidney failure and premature death, according to a new review led by University of Manchester and Northern Care Alliance NHS Foundation Trust researchers.

10 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Research makes strong case for broader use of GLP1 drugs to protect hearts

Semaglutide cuts major heart events, but researchers still cannot fully explain why

GLP-1s linked to nutritional deficiencies in children

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Semaglutide’s heart benefits may extend beyond weight loss

Experimental RNA therapy enhances weight loss while preserving lean muscle

GLP-1 medications place children at risk for nutritional deficiencies

New discovery overturns a prevailing model of brain development

New AACR report outlines future of cutting-edge cancer research

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

Symptomless liver condition linked to heart and kidney disease

GLP-1 treatment linked to 40% fewer asthma attacks

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

Dual-drug microneedle patch targets inflammation and fat browning

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

Semaglutide extended lifespan in older female mice, but that was not the only finding

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

GLP 1 Agonists News and Research

Latest GLP 1 Agonists News and Research

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Newsletters you may be interested in